Brief: IMPACT Therapeutics Signs Exclusive License Deal With Pharmanovia For Senaparib In Europe, Others
30/07/2026 11:21
BRIEF-IMPACT Therapeutics Signs Exclusive License Deal With Pharmanovia For Senaparib In Europe, Others July 30 (Reuters) - IMPACT Therapeutics Inc 7630.HK:
EXCLUSIVE LICENSE AGREEMENT WITH PHARMANOVIA FOR SENAPARIB IN EUROPE, MIDDLE EAST AND NORTH AFRICA, AUSTRALIA AND NEW ZEALAND
ELIGIBLE FOR UP TO EUR 423.50 MLN PLUS TIERED ROYALTIES IN PHARMANOVIA DEAL
Further company coverage: 7630.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IMPACT Therapeutics
See all newsBrief: Impact Therapeutics Says Senaparib Submitted To European Commission For Final Marketing Authorization Decision
Brief: Impact Therapeutics Says CEO Purchases 100,000 Ordinary Shares At HK$14.6105 Per Share
Brief: IMPACT Therapeutics Signs Exclusive License Deal With Pharmanovia For Senaparib In Europe, Others
Metis TechBio, IMPACT Therapeutics shine in Hong Kong debut
Brief: Impact Therapeutics Says Final Offer Price Under Global Offering Of Hk$20.10 Per H Share